Regulatory T cells (Tregs) are crucial players in the immune system, and their role in cancer is complex and multifaceted. While Tregs are essential for preventing autoimmune reactions and regulating immune responses, they can also be exploited by tumors to create an immunosuppressive environment, aiding tumor progression. This delicate balance makes Tregs a fascinating and challenging target for cancer immunotherapy.
The tumor microenvironment (TME) is a dynamic ecosystem where Tregs interact with various cells and factors. Tumor cells recruit and maintain Tregs by releasing specific cytokines and chemical factors, leading to their aggregation in tumor tissue. This creates a suppressive immune microenvironment that benefits the tumor's growth and evasion of the immune system.
However, the story doesn't end there. Tregs have a dual role in cancer. While they can contribute to adverse outcomes, some studies suggest they may also lead to better survival in cancer patients. For instance, a high rate of FOXP3+ tumor-infiltrating lymphocytes has been linked to improved prognosis in certain cancers, such as estrogen receptor-negative breast cancer, colorectal cancer, and ovarian cancer.
This paradoxical behavior of Tregs is attributed to their heterogeneous functions and phenotypes, as well as the complex cell communications within the TME. Understanding these intricacies is crucial for developing effective cancer treatments.
Enter extracellular vesicles (EVs), nanoscale particles secreted by all cells. EVs play a significant role in intercellular communication, immune responses, and disease development. They carry various biological molecules, including RNA, proteins, lipids, and metabolites, and are considered essential mediators of cell-to-cell communication.
EVs have been extensively studied in the context of tumors, revealing their wide-ranging effects on tumor progression. They can influence tumor proliferation, metastasis, immune evasion, metabolism reprogramming, treatment resistance, and angiogenesis. Moreover, EVs are ideal drug carriers due to their natural biocompatibility and low immunogenicity, making them a promising tool in cancer treatment.
Recent research has uncovered the effects of EVs on Tregs, and the findings are intriguing. Studies suggest that EVs from various sources, including tumor cells, adipocytes, endothelial cells, macrophages, and stem cells, can influence the proliferation, differentiation, expansion, and metabolism of Tregs. This crosstalk between EVs and Tregs is a rapidly emerging area of research, with potential implications for cancer treatment.
For instance, EVs from head and neck cancer cells have been shown to carry TGF-β1 and IL-10, which can induce the differentiation of CD4+CD25+ Tregs from CD4+CD25− T cells, promoting Treg proliferation and immunosuppression. Similar effects have been observed in other cancers, such as esophageal cancer, gastric cancer, hepatocellular carcinoma, and pancreatic cancer.
However, it's not all one-sided. Some studies suggest that EVs from certain sources can have inhibitory effects on Tregs. For example, EVs from CT26 colon cancer cells and Colon-26 colon cancer cells have been shown to reduce the number of Tregs and downregulate the expression of FoxP3 in Treg, exerting anti-tumor immune effects.
The heterogeneity of EVs is a key factor in their diverse roles in tumor immune regulation. The molecular composition of EVs, which includes proteins, nucleic acids, and lipids, directly influences their function. Even EVs derived from the same source can exhibit completely different functions due to differences in their molecular cargo.
Treg-derived EVs are also an area of interest. These EVs carry immunosuppressive molecules like CD73, contributing to the formation of a Treg cell-mediated immunosuppressive microenvironment. They can also carry miRNAs that inhibit the functions of other immune cells, such as pathogenic T helper 1 cells and macrophages.
The clinical potential of targeting EVs and utilizing them as drug delivery tools is immense. Reducing Treg-beneficial EVs could be a helpful strategy for cancer treatment. Some methods, such as RAB27A knockdown, GW4869, and the novel AH-D peptide, have shown promise in targeting Treg-beneficial EVs.
Engineered EVs, including native EVs, pre-generation modified, post-generation modified, and hybrid EVs, are being explored as drug delivery systems. These EVs can be tailored to deliver specific therapeutic molecules, offering precision applications such as Treg-targeted EV therapy for cancer treatment.
The wide-ranging effects of EVs on Tregs highlight the importance of targeting tumor-promoting EVs. While there are challenges to be addressed before EV-related therapy can enter clinical practice, the emerging work in this field promises a better understanding of tumors and improved treatment strategies in the future.
